All In Biotech

Drug Trial Radar · NCT05283395

Rocklatan® Evaluation

A Multicenter, Open-Label Rocklatan® (Netarsudil/Latanoprost Ophthalmic Solution) 0.02%/0.005% Evaluation of IOP Lowering Efficacy and Safety as Replacement of Current Medical Therapy Regimen for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension

Last checked: Nov 20, 2026Latest source record: Apr 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

136

Actual

Start

Mar 28, 2022

Primary completion

Mar 22, 2023

Study completion Mar 22, 2023

Sponsor

Lead sponsor
Aerie PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Mar 17, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate the IOP-lowering effect when subjects are switched from various latanoprost-based regimens to Rocklatan. Subjects will stop their IOP-lowering medical therapy regimen and dose with Rocklatan for the duration of the study (12 weeks).

Conditions

  • Glaucoma

Interventions

  • Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solutionDrug

    Commercially available ophthalmic solution indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Percent Change From Baseline in Intraocular Pressure (IOP) at Week 12Time frame: Baseline (Day 0 pretreatment), Week 12

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • North Valley Eye Medical Group

    Mission Hills, California

  • Visionary Eye Institute

    Newport Beach, California

  • California Eye Specialists Medical Group

    Pasadena, California

  • North Bay Eye Associates

    Petaluma, California

  • Shettle Eye Research

    Largo, Florida

  • Center For Sight

    Venice, Florida

  • Georgia Eye Partners

    Atlanta, Georgia

  • Coastal Research Associates LLC

    Roswell, Georgia

  • Tekwani Vision Center

    St Louis, Missouri

  • OCLI Vision

    Manhasset, New York

  • Mark J. Weiss, MD, Inc.

    Tulsa, Oklahoma

  • Scott & Christie and Associates, PC

    Cranberry Township, Pennsylvania

  • Advancing Vision Research

    Goodlettsville, Tennessee

  • VRF Eye Specialty Group

    Memphis, Tennessee

  • Total Eye Care, PA

    Memphis, Tennessee

  • Keystone Research

    Austin, Texas

  • Louis M. Alpern, M.D., M.P.H., P.A

    El Paso, Texas

  • Houston Eye Associates

    Houston, Texas

  • Emerson Clinical Research Institute

    Falls Church, Virginia

  • Vistar Eye Center

    Roanoke, Virginia

  • The Eye Centers of Racine and Kenosha

    Racine, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.